Drug Profile

REGN 7508

Alternative Names: REGN-7508

Latest Information Update: 22 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regeneron Pharmaceuticals
Class Antithrombotics; Monoclonal antibodies
Mechanism of Action Factor XI inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Venous thromboembolism
Phase I Thrombosis

Most Recent Events

16 Sep 2025 Regeneron Pharmaceuticals plans a phase II ROXI-ATLAS trial for Atrial Fibrillation (Prevention) in October 2025 (NCT07175428)
01 Aug 2025 Regeneron Pharmaceuticals plans additional phase-III trials later this year and first half of 2026
09 Jul 2025 Regeneron Pharmaceuticals completes a phase I trial (In volunteers, Combination therapy) in United Kingdom (IV) (NCT06444178)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com